Get access

Clinical Outcome of Nonnasal Chondrosarcoma in Dogs: Thirty-One Cases (1986–2003)

Authors

  • SUZANNE SHELLY WALTMAN DVM Diplomate ACVIM (Oncology),

    1. Department of surgical and Radiological Science, School of Veterinary Medicine, University of California, Davis, CA
    2. College of Veterinary Medicine, Oregon State University, Corvallis, OR
    3. Southwest Veterinary Oncology, Glendale, AZ
    Search for more papers by this author
  • BERNARD SEGUIN DVM Diplomate ACVS,

    1. Department of surgical and Radiological Science, School of Veterinary Medicine, University of California, Davis, CA
    2. College of Veterinary Medicine, Oregon State University, Corvallis, OR
    3. Southwest Veterinary Oncology, Glendale, AZ
    Search for more papers by this author
  • BARRY J. COOPER BVSc, PhD, Diplomate ACVP,

    1. Department of surgical and Radiological Science, School of Veterinary Medicine, University of California, Davis, CA
    2. College of Veterinary Medicine, Oregon State University, Corvallis, OR
    3. Southwest Veterinary Oncology, Glendale, AZ
    Search for more papers by this author
  • MICHAEL KENT DVM, Diplomate ACVIM (Oncology) & ACVR (Radiation Oncology)

    1. Department of surgical and Radiological Science, School of Veterinary Medicine, University of California, Davis, CA
    2. College of Veterinary Medicine, Oregon State University, Corvallis, OR
    3. Southwest Veterinary Oncology, Glendale, AZ
    Search for more papers by this author

  • All work performed within the Department of Surgical and Radiological Sciences, Tupper Hall Room 2112, School of Veterinary Medicine, University of California at Davis, Davis CA 95616.

Address reprints requests to Dr. Michael Kent, DVM, Diplomate ACVIM (Oncology) & ACVR (Radiation Oncology), Department of Surgical and Radiological Sciences, Tupper Hall Room 2112, School of Veterinary Medicine, University of California—Davis, Davis, CA 95616. E-mail: mskent@ucdavis.edu.

Abstract

Objective— To evaluate metastatic rate and survival times of dogs with chondrosarcoma of nonnasal bony sites treated by wide surgical excision.

Study Design— Retrospective study.

Animals— Dogs (n=31) with chondrosarcoma.

Methods— Medical records were retrospectively reviewed to identify dogs with chondrosarcoma of bone in potentially surgically accessible sites. When complete information was not available in the medical record, owners and referring veterinarians were contacted by telephone to evaluate the course of disease and survival times. When possible, histopathologic diagnosis was confirmed by a single board certified pathologist and tumors were histologically graded.

Results— Dogs treated by wide surgical excision (n=18) had a mean survival time of 3097 days and did not reach median survival time. Dogs untreated except for diagnostic biopsy (n =13) had a median survival time of 523 days and a mean survival time of 495 days. Method of treatment and tumor grade predicted survival time (P=.016 and P=.007, respectively). Metastatic rate was 28% for treated dogs and 15% for untreated dogs, with no significant difference between the 2 groups (P=.39).

Conclusions— Wide surgical excision significantly improves survival time for dogs with chondrosarcoma of nonnasal bony sites, but does not affect the likelihood of metastasis. Grade may be prognostic for survival.

Clinical Relevance— Surgical excision benefits dogs with chondrosarcoma and can result in prolonged survival times. Metastasis still occurs in ∼1 of 4 dogs even after surgical resection.

Ancillary